Abstract
Genome-wide association studies (GWASs) have identified tens of thousands of disease associated variants and provided critical insights into developing effective treatments. However, limited sample sizes have hindered the discovery of variants for uncommon and rare diseases. Here, we introduce KGWAS, a novel geometric deep learning method that leverages a massive functional knowledge graph across variants and genes to improve detection power in small-cohort GWASs significantly. KGWAS assesses the strength of a variant’s association to disease based on the aggregate GWAS evidence across molecular elements interacting with the variant within the knowledge graph. Comprehensive simulations and replication experiments showed that, for small sample sizes (N=1-10K), KGWAS identified up to 100% more statistically significant associations than state-of-the-art GWAS methods and achieved the same statistical power with up to 2.67× fewer samples. We applied KGWAS to 554 uncommon UK Biobank diseases (Ncase <5K) and identified 183 more associations (46.9% improvement) than the original GWAS, where the gain further increases to 79.8% for 141 rare diseases (Ncase <300). The KGWAS-only discoveries are supported by abundant functional evidence, such as rs2155219 (on 11q13) associated with ulcerative colitis potentially via regulating LRRC32 expression in CD4+ regulatory T cells, and rs7312765 (on 12q12) associated with the rare disease myasthenia gravis potentially via regulating PPHLN1 expression in neuron-related cell types. Furthermore, KGWAS consistently improves downstream analyses such as identifying disease-specific network links for interpreting GWAS variants, identifying disease-associated genes, and identifying disease-relevant cell populations. Overall, KGWAS is a flexible and powerful AI model that integrates growing functional genomics data to discover novel variants, genes, cells, and networks, especially valuable for small cohort diseases.
Competing Interest Statement
Soner Koc, Alexandra Pettet, Laurence Howe, Tom Richardson, Adrian Cortes, Katie Aiello, and Kim Branson are employees of GSK and report ownership of GSK shares and/or restricted GSK shares.
Funding Statement
K.H. acknowledges support from the Stanford Bio-X Lubert Stryer Interdisciplinary Graduate Fellowship. T.Z. acknowledges support from the Stanford Genetics and Developmental Biology Training Program. J.M.E. acknowledges support from the NHGRI Impact of Genomic Variation on Consortium (UM1HG011972); the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease (NNF21SA0072102); Gordon and Betty Moore and the BASE Research Initiative at the Lucile Packard Childrens Hospital at Stanford University. M.J.Z. acknowledges the support of the Shurl and Kay Curci Foundation. J.L. acknowledges the support of NSF under Nos. OAC-1835598 (CINES), CCF-1918940 (Expeditions), DMS-2327709 (IHBEM), IIS-2403318 (III); Stanford Data Applications Initiative, Wu Tsai Neurosciences Institute, Stanford Institute for Human-Centered AI, Chan Zuckerberg Initiative, Amazon, Genentech, GSK, Hitachi, SAP, and UCB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank resource under Application Number 79791. The UK Biobank has ethical approval from the North West Multi-centre Research Ethics Committee (REC reference: 11/NW/0382), and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The KGWAS knowledge graph and variant/gene/program annotations, summary statistics of GWAS/FINDOR/KGWAS of null, causal simulations, and 21 well-powered independent UK Biobank disease/traits across different sample sizes, summary statistics of GWAS/KGWAS of 554 uncommon diseases are all publicly available at Harvard Dataverse under https://doi.org/10.7910/DVN/C45SO2.
